Efficacy and Safety Outcomes of Intravitreal Dexamethasone Implant Therapy for the Treatment of Adult Coats’ Disease

Table 3

Treatments and retinal outcome details of patients with Stage 3A Coats’ disease.

Case no.	Baseline BCVA (logMAR)	Initial treatments	Additional treatment	Reason for additional treatment	Time to additional treatment	Following time (months)	Final BCVA (logMAR)	Final retinal outcome
Case 1	1	DEX, VC, and laser	—		—	16	0.1	Reattachment of ERD, lipid exudative absorbed
Case 2	1.398	DEX, followed by laser after 1 month	Anti-VEGF	Retinal haemorrhage, leakage of retinal telangiectasia	3 months	6	1.0	Reattachment of ERD, lipid exudative absorbed
Case 3	FC/30 cm	Laser, DEX	—		—	12	1.85	Macular subretinal scar
Case 4	FC/30 cm	Laser, DEX	Anti-VEGF	Macular ERD, neovascularization	1 week	6	1.0	Persistence ERD
Case 5	1.301	Laser, DEX	DEX	Recurrent macular ERD	10 months	18	1.0	Reattachment of ERD, lipid exudative absorbed
Case 6	0.301	Laser, DEX	Anti-VEGF	Macular ERD	1 week	6	0.1	Reattachment of ERD, lipid exudative absorbed
Case7	0.523	Laser, IVC	—		—	8	0.8	Persistence ERD
Case 8	0.523	Laser, IVC	TTT	Temporal and nasal side capillary telangiectasia	8 months	8	0.5	Persistence ERD
Case 9	1.85	Laser, IVC	PPV	Extensive posterior pole ERD, macular hole	4 months	6	1.85	Persistence ERD
Case 10	0.5	Laser, IVC	—		—	11	0.7	Reattachment of ERD, lipid exudative reduced

BCVA: best-corrected visual acuity. logMAR: 10 logarithm of minimum angle of resolution letters. CRT: central retinal thickness. IOP: intraocular pressure. DEX: dexamethasone intravitreal implant. IVC: intravitreal injection of conbercept. PPV: pars plana vitrectomy. ERD: exudative retinal detachment. TTT: transpupillary thermotherapy.